Research information only, not medical advice. Research peptide, not approved for human use anywhere. Up for an FDA advisory committee vote on July 23, 2026 (evaluated indication: Wound healing and inflammatory conditions). Removed from the FDA 'do not compound' list in April 2026 but not yet compoundable.
KPV at a glance
As of June 2026 the human evidence is limited; most data is preclinical. See the indexed studies below, graded by evidence level.
The peptides on the agenda are covered in the July 2026 FDA peptide meeting .
Evidence profile
53 studies- Human trial 1 · 2%
- Review 4 · 8%
- Animal 14 · 26%
- In-vitro 19 · 36%
- Unknown 15 · 28%
The longer the green, the stronger the human evidence. For most research peptides the bar is dominated by animal and in-vitro work, which is a signal to read every claim carefully.
Regulatory status
- 2026-04-22 US-FDA
Removed from the FDA 503A 'do not compound' Category 2 (nominations withdrawn) — still not eligible for compounding. source
- 2026-07-23 US-FDA · upcoming
FDA Pharmacy Compounding Advisory Committee vote (evaluated indication: Wound healing and inflammatory conditions); docket FDA-2025-N-6895. source
Indexed research
Sorted by evidence level, strongest first.
- Human trial 2026Project Title:"A 3-Month Pilot Pre-Trial of a Multi-Peptide Protocol (BPC-157/KPV/GHK-Cu Blend + TB-500 + Ara290 + Semax) for Arthritis, Cartilage Repair, Neuropathic Pain, and Mobility in Older Adults
This pilot pre-trial investigates a multi-peptide protocol in older adults for arthritis, cartilage repair, neuropathic pain, and mobility over 3 months.
- Review 2026A new era of doping? Use of peptide and peptide-analog drugs in recreational and professional sport and bodybuilding: a critical review
This critical review examines the limited clinical evidence and potential risks of peptide and peptide-analog drugs used for performance enhancement in sport and bodybuilding.
- Review 2025Host defense peptides as a new drug lead to a strategy for inflammatory bowel disease
- Review 2025Exploring the Role of Tripeptides in Wound Healing and Skin Regeneration: A Comprehensive Review
- Review 2026REGENERATIVE PEPTIDES IN MUSCULOSKELETAL MEDICINE: COMPARATIVE MECHANISMS OF BPC-157, THYMOSIN BETA-4/TB-500, TB-500 FRAGMENT AND KPV IN OSTEOMYOARTICULAR REPAIR
This integrative review analyzes the biological mechanisms and translational potential of BPC-157, Thymosin Beta-4, TB-500, TB-500 Fragment, and KPV in musculoskeletal regeneration, concluding that while findings are promising, further controlled clinical trials are needed.
- Animal 2026NLRP3 autophagic degradation disruption in melanocytes contributes to vitiligo development
- Animal 2026Inflammation-triggered self-immolative conjugates enable oral peptide delivery by overcoming gastrointestinal barriers
- Animal 2024PepT1-targeted nanodrug based on co-assembly of anti-inflammatory peptide and immunosuppressant for combined treatment of acute and chronic DSS-induced ColitiS
- Animal 2024A nanoparticle platform for combined mucosal healing and immunomodulation in inflammatory bowel disease treatment
This study developed hybrid lipid hyaluronate-KPV conjugated nanoparticles loaded with teduglutide for combined mucosal healing and immunomodulation in an animal model of inflammatory bowel disease.
- Animal 2023Vimentin is required for tumor progression and metastasis in a mouse model of non-small cell lung cancer
+ 43 more studies indexed for KPV.
Frequently asked questions
- Is KPV approved for human use?
- Research peptide, not approved for human use anywhere. Up for an FDA advisory committee vote on July 23, 2026 (evaluated indication: Wound healing and inflammatory conditions). Removed from the FDA 'do not compound' list in April 2026 but not yet compoundable.
- What does the research on KPV show?
- As of June 2026 the human evidence is limited; most data is preclinical. See the indexed studies below, graded by evidence level.